Personalised radioembolization improves outcomes in refractory intra-hepatic cholangiocarcinoma: a multicenter study.
Adult
Aged
Aged, 80 and over
Cholangiocarcinoma
/ drug therapy
Embolization, Therapeutic
Female
Fluorodeoxyglucose F18
Humans
Liver Neoplasms
/ diagnostic imaging
Lymphatic Metastasis
Male
Middle Aged
Positron Emission Tomography Computed Tomography
Precision Medicine
Proportional Hazards Models
Retrospective Studies
Technetium Tc 99m Aggregated Albumin
Treatment Outcome
Yttrium Radioisotopes
/ therapeutic use
Intra-hepatic cholangiocarcinoma
Radioembolization
Resin microspheres
SIRT
Yttrium-90
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
05
04
2019
accepted:
03
07
2019
pubmed:
22
7
2019
medline:
21
10
2020
entrez:
21
7
2019
Statut:
ppublish
Résumé
Reported outcomes of patients with intra-hepatic cholangiocarcinoma (IH-CCA) treated with radioembolization are highly variable, which indicates differences in included patients' characteristics and/or procedure-related variables. This study aimed to identify patient- and treatment-related variables predictive for radioembolization outcome. This retrospective multicenter study enrolled 58 patients with unresectable and chemorefractory IH-CCA treated with resin Median OS (mOS) post-radioembolization of the entire cohort was 10.3 months. Variables associated with significant differences in terms of OS were serum albumin (hazard ratio (HR) = 2.78, 95%CI:1.29-5.98, p = 0.002), total bilirubin (HR = 2.17, 95%CI:1.14-4.12, p = 0.009), aspartate aminotransferase (HR = 2.96, 95%CI:1.50-5.84, p < 0.001), alanine aminotransferase (HR = 2.02, 95%CI:1.05-3.90, p = 0.01) and γ-GT (HR = 2.61, 95%CI:1.31-5.22, p < 0.001). The presence of lymph node metastasis as well as a TLR Radioembolization efficacy in patients with unresectable recurrent and/or chemorefractory IH-CCA strongly depends on the tumor radiation dose. Personalized activity prescription should be performed.
Identifiants
pubmed: 31324943
doi: 10.1007/s00259-019-04427-z
pii: 10.1007/s00259-019-04427-z
doi:
Substances chimiques
Technetium Tc 99m Aggregated Albumin
0
Yttrium Radioisotopes
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
2270-2279Références
Phys Med Biol. 2008 Nov 21;53(22):6591-603
pubmed: 18978442
Semin Intervent Radiol. 2017 Jun;34(2):92-100
pubmed: 28579676
Liver Int. 2017 Jul;37(7):1056-1064
pubmed: 28177190
J Nucl Med. 2009 May;50 Suppl 1:122S-50S
pubmed: 19403881
J Nucl Med. 2012 Feb;53(2):255-63
pubmed: 22302962
EJNMMI Res. 2018 Jul 13;8(1):60
pubmed: 30006851
J Vasc Interv Radiol. 2015 Nov;26(11):1615-21
pubmed: 26321017
Eur J Nucl Med. 1996 Aug;23(8):947-52
pubmed: 8753684
Eur J Nucl Med Mol Imaging. 2011 Jun;38(6):1037-45
pubmed: 21308371
Lancet Oncol. 2017 Sep;18(9):1159-1171
pubmed: 28781171
Ann Surg Oncol. 2008 Feb;15(2):600-8
pubmed: 17987347
BMC Cancer. 2014 Jul 09;14:497
pubmed: 25011439
J Nucl Med. 2016 Jul;57(7):1014-9
pubmed: 26912436
BMC Cancer. 2014 Dec 01;14:897
pubmed: 25487708
Eur J Nucl Med Mol Imaging. 2016 Sep;43(10):1792-801
pubmed: 27072811
Am J Gastroenterol. 2010 May;105(5):1123-32
pubmed: 19997097
Front Oncol. 2014 Aug 19;4:210
pubmed: 25191640
Cardiovasc Intervent Radiol. 2013 Apr;36(2):440-8
pubmed: 22956045
Eur J Nucl Med Mol Imaging. 2018 Sep;45(10):1731-1741
pubmed: 29560519
Ann Surg Oncol. 2010 Feb;17(2):484-91
pubmed: 19876691
J Nucl Med. 2012 Apr;53(4):559-66
pubmed: 22343503
J Nucl Med. 2011 Dec;52(12):1930-7
pubmed: 22068894
EJNMMI Res. 2017 Dec;7(1):46
pubmed: 28536968
Lancet Oncol. 2010 Jan;11(1):48-54
pubmed: 19932054
HPB (Oxford). 2008;10(2):77-82
pubmed: 18773060
Cardiovasc Intervent Radiol. 2012 Feb;35(1):105-16
pubmed: 21431970
Gut Liver. 2009 Dec;3(4):298-305
pubmed: 20431764
N Engl J Med. 2010 Apr 8;362(14):1273-81
pubmed: 20375404